Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2014

View Archived Issues

Mission Therapeutics develops new DUB inhibitors

RIPK3, a potential drug target for Gaucher's disease

Aduro BioTech presents new vaccine platforms

GSTM4 gene as a candidate biomarker for eczema herpeticum

Lilly discloses new homodimeric proteins

Merck & Co patents new SYK inhibitors

Ipsen reports findings from phase IIa study of Dysport for neurogenic detrusor overactivity

New NHE-3 inhibitors patented by Ardelyx and AstraZeneca

Lupin designs new CaSR agonists

Cellular Biomedicine Group begins study of stem cell treatment for asthma

AstraZeneca provides update on global PARTHENON program

Astellas and Medivation submit sNDA for Xtandi in the U.S.

Novel HIV-1 maturation inhibitor candidates with improved profile

Pharma Two B begins phase IIb study of fixed-dose combination therapy P2B-001

Trovagene introduces NGS-based KRAS oncogene mutation assay

First patient dosed in phase Ib/II trial of CRLX-101 in rectal cancer

First patient enrolled in phase II trial of G-202 in glioblastoma multiforme

FDA extends PDUFA date for Biogen Idec's Plegridy BLA

Igenica Biotherapeutics doses first patient in phase I study of IGN-523

Dainippon Sumitomo Pharma presents a novel potent and selective 11beta-HSD1 inhibitor

Avedro receives FDA complete response letter for corneal cross-linking system

Advaxis and UCSF to assess cancer immunotherapy constructs

Medigene licenses RhuDex rights to Dr. Falk Pharma for hepatology and gastroenterology

Maruho seeks Japanese approval of benzoyl peroxide for acne vulgaris

Bionomics announces results of phase II trial of BNC-105 in renal cancer

Peptide triazole KR-13 induces cell-free HIV-1 virolysis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...